drugset / Trial / NCT01016600
Azacitidine and Lenalidomide for Acute Myeloid Leukemia
Phase 1/2
Completed
31 enrolled
Washington University School of Medicine
Celgene Corporation · collab
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Determine toxicity and remission rates of treatment with azacitidine and lenalidomide for patients with Acute Myeloid Leukemia
Timeline
- Start
- 2010-04
- Primary completion
- 2013-11
- Completion
- 2014-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Azacitidine | Other / unclassified | 75 mg/m2 | Intravenous |
| Subject | Lenalidomide | Other / unclassified | 10 mg | Oral |